bioAffinity Technologies, Inc. Increase (Decrease) in Accrued Liabilities
bioAffinity Technologies, Inc. (BIAF) reported Increase (Decrease) in Accrued Liabilities of -$303.50 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-07
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$614.35K.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $310.86K.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $733.44K, a 48.33% increase year-over-year.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$63.49K.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $319.27K, a 28.27% increase from fiscal 2024.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $248.91K, a 31.24% decline from fiscal 2023.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $362.01K, a 445.73% increase from fiscal 2022.
- bioAffinity Technologies, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $66.33K, a 38.43% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$614.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$303.50K 10-Q · filed 2026-08-07 | $429.94K derived: sum of 3 quarters · filed 2026-08-07 | $366.46K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $310.86K 10-Q · filed 2026-05-11 | $1.04M derived: sum of 2 quarters · filed 2026-05-11 | $980.81K derived: sum of 3 quarters · filed 2026-05-11 | $658.11K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $733.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $669.96K derived: sum of 2 quarters · filed 2026-03-16 | $347.25K derived: sum of 3 quarters · filed 2026-08-07 | $319.27K 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$63.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$386.19K derived: sum of 2 quarters · filed 2026-08-07 | -$414.18K 10-Q · filed 2025-11-14 | $80.30K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | -$322.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$350.69K 10-Q · filed 2026-08-07 | $143.78K derived: sum of 3 quarters · filed 2026-08-07 | $78.94K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$27.99K 10-Q · filed 2026-05-11 | $466.48K derived: sum of 2 quarters · filed 2026-05-11 | $401.64K derived: sum of 3 quarters · filed 2026-05-11 | $487.42K derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $494.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $429.63K derived: sum of 2 quarters · filed 2026-03-16 | $515.40K derived: sum of 3 quarters · filed 2026-03-16 | $248.91K 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$64.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $20.93K derived: sum of 2 quarters · filed 2025-11-14 | -$245.56K 10-Q · filed 2025-11-14 | $260.47K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $85.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$180.72K 10-Q · filed 2025-08-14 | $325.31K derived: sum of 3 quarters · filed 2025-08-14 | $207.53K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$266.49K 10-Q · filed 2025-05-15 | $239.53K derived: sum of 2 quarters · filed 2025-05-15 | $121.75K derived: sum of 3 quarters · filed 2025-05-15 | $156.08K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $506.02K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $388.24K derived: sum of 2 quarters · filed 2025-03-31 | $422.57K derived: sum of 3 quarters · filed 2025-03-31 | $362.01K 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$117.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$83.46K derived: sum of 2 quarters · filed 2024-11-14 | -$144.01K 10-Q · filed 2024-11-14 | -$76.15K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $34.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$26.23K 10-Q · filed 2024-08-14 | $41.63K derived: sum of 3 quarters · filed 2024-08-14 | $82.83K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$60.56K 10-Q · filed 2024-05-15 | -$60.56K 10-Q · filed 2023-05-15 | $7.30K derived: sum of 2 quarters · filed 2024-05-15 | $48.51K derived: sum of 3 quarters · filed 2024-05-15 | $35.43K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $67.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $109.06K derived: sum of 2 quarters · filed 2024-04-01 | $95.98K derived: sum of 3 quarters · filed 2024-04-01 | $66.33K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $41.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $28.13K derived: sum of 2 quarters · filed 2023-11-14 | -$1.52K 10-Q · filed 2023-11-14 | $106.49K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$13.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$42.73K 10-Q · filed 2023-08-14 | $65.28K derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$29.65K 10-Q · filed 2023-05-15 | $78.36K derived: sum of 2 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $108.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $107.74K 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$269.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |